Matthias Kant
Overview
Explore the profile of Matthias Kant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pontieri L, Greene N, Wandall-Holm M, Geertsen S, Asgari N, Jensen H, et al.
Brain Commun
. 2024 Dec;
6(6):fcae422.
PMID: 39713244
Currently, there are limited therapeutic options for patients with non-active secondary progressive multiple sclerosis. Therefore, real-world studies have investigated differences between patients with relapsing-remitting multiple sclerosis, non-active secondary progressive multiple...
2.
Frederiksen J, Massacesi L, Nielsen H, Rini A, Baldi E, Mirabella M, et al.
Mult Scler Relat Disord
. 2024 Dec;
93:106214.
PMID: 39642455
Background: Alemtuzumab is approved in the European Union for treating highly active relapsing-remitting multiple sclerosis (RRMS). Patient-reported outcomes measure the treatment impact on quality of life (QoL), including fatigue, a...
3.
Framke E, Sellebjerg F, Kant M, Stilund M, Jensen H, Illes Z, et al.
Mult Scler
. 2024 Dec;
31(1):36-43.
PMID: 39632560
Background: Teriflunomide has been associated with an increased risk of hypertension. Real-world studies including adequate control groups are lacking. We hypothesized that patients with multiple sclerosis (MS) treated with teriflunomide...
4.
Mahler M, Magyari M, Pontieri L, Elberling F, Holm R, Weglewski A, et al.
J Neurol Neurosurg Psychiatry
. 2024 Apr;
95(10):979-987.
PMID: 38569873
Background: Clinicians frequently rely on relapse counts, T2 MRI lesion load (T2L) and Expanded Disability Status Scale (EDSS) scores to guide treatment decisions for individuals diagnosed with multiple sclerosis (MS)....
5.
Spelman T, Magyari M, Butzkueven H, van der Walt A, Vukusic S, Trojano M, et al.
Front Neurol
. 2024 Jan;
14:1274194.
PMID: 38187157
Background: Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors...
6.
Roar M, Hogh Nielsen A, Berg J, Sirakov G, Stilund M, Schafer J, et al.
Mult Scler Relat Disord
. 2023 Nov;
80:105127.
PMID: 37956521
Background: Adherence is a prerequisite for the efficacy of any drug, and previous studies have shown that non-adherence is associated with disease activity and increased health care cost in multiple...
7.
Hansen J, Gustavsen S, Roshanisefat H, Kant M, Biering-Sorensen F, Andersen C, et al.
Pharmaceuticals (Basel)
. 2023 Aug;
16(8).
PMID: 37630995
Patients with multiple sclerosis (MS) and spinal cord injury (SCI) commonly sustain central neuropathic pain (NP) and spasticity. Despite a lack of consistent evidence, cannabis-based medicine (CBM) has been suggested...
8.
Roos I, Hughes S, McDonnell G, Malpas C, Sharmin S, Boz C, et al.
JAMA Neurol
. 2023 Jun;
80(8):789-797.
PMID: 37307006
Importance: Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting...
9.
Buron M, Romme Christensen J, Pontieri L, Joensen H, Kant M, Rasmussen P, et al.
Mult Scler Relat Disord
. 2023 Apr;
74:104713.
PMID: 37058764
Background: Natalizumab is a widely used high-efficacy treatment in multiple sclerosis (MS). Real-world evidence regarding long-term effectiveness and safety is warranted. We performed a nationwide study evaluating prescription patterns, effectiveness,...
10.
Ravn J, Jensen H, Kant M, Andersen P, Gora M, Sejbaek T
Mult Scler Relat Disord
. 2022 Aug;
67:104081.
PMID: 35944466
Background: Dimethyl fumarate (DMF, Tecfidera®) is a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis. Lymphopenia is a frequent reason for discontinuation in fumarate-treated patients. Management strategies to minimize risk of...